Denmark· DK-28105883016
Mylotarg
A gemtuzumab ozogamicin product containing gemtuzumab ozogamicin, registered in Denmark by Pfizer Europe MA EEIG. The same ATC class is registered in 12 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Gemtuzumab ozogamicin is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FX02 (gemtuzumab ozogamicin), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 8 of them publish a price we can compare per daily dose
Gemtuzumab ozogamicin · ATC L01FX02
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Gemtuzumab ozogamicin
- Manufacturer
- Pfizer Europe MA EEIG
- Country
- Denmark (DK)
- ATC code
- L01FX02
- ATC class
- Gemtuzumab ozogamicin
- Defined daily dose
- 2.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28105883016
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
112 interactions on record for gemtuzumab ozogamicin.
Graded by severity as the source publishes them — 33 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Gemtuzumab ozogamicin · interactions on record
112 records
- 33 severe
- 64 moderate
- 15 minor
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- CladribineL01BB04severe
- PexidartinibL01EX15severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01FX02
Gemtuzumab ozogamicin, as other registers publish it.
- United StatesMylotargWyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
- NorwayMylotargPfizer Europe MA EEIG (1)
- PolandMylotargPfizer Europe MA EEIG
- IcelandMylotargPfizer Europe MA EEIG*
- CzechiaMYLOTARGPfizer Europe MA EEIG, Bruxelles
- FinlandMYLOTARGPfizer Europe MA EEIG
- CanadaMYLOTARGPFIZER CANADA ULC
- BelgiumMylotarg 5 mgPfizer Europe MA
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0d2d469b-269d-45f8-8899-3710e657b3c3 GET /v1/drugs/0d2d469b-269d-45f8-8899-3710e657b3c3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "pulver til koncentrat til infusionsvæske, opløsning",
"source": "dkma",
"strength": "5 mg",
"auth_role": "RAP",
"dk_drugid": "28105883016",
"substance": "Gemtuzumab ozogamicin",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "43209"
}See everything about gemtuzumab ozogamicin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.